Aficamten
A cardiac myosin inhibitor used in the treatment of hypertrophic cardiomyopathy
| Aficamten | |
|---|---|
[[File: | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | |
| KEGG | D12345 |
Aficamten is a cardiac myosin inhibitor that is being developed for the treatment of hypertrophic cardiomyopathy (HCM). It is designed to reduce the hypercontractility of the heart muscle, which is a hallmark of this condition.
Mechanism of Action[edit]
Aficamten works by selectively inhibiting cardiac myosin, a motor protein responsible for heart muscle contraction. By reducing the activity of myosin, aficamten decreases the force of contraction of the heart muscle, thereby alleviating the symptoms associated with hypertrophic cardiomyopathy. This mechanism helps in reducing the left ventricular outflow tract obstruction, which is a common problem in HCM patients.
Clinical Development[edit]
Aficamten is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hypertrophic cardiomyopathy. Early studies have shown promising results in terms of reducing cardiac muscle contractility and improving symptoms in patients with obstructive HCM.
Pharmacokinetics[edit]
The pharmacokinetic profile of aficamten includes oral administration, with studies indicating a favorable absorption and distribution in the body. The drug is metabolized primarily in the liver and excreted through the kidneys. The half-life of aficamten allows for once-daily dosing, which is convenient for patients.
Potential Side Effects[edit]
As with any medication, aficamten may have side effects. Commonly reported side effects include dizziness, fatigue, and hypotension. It is important for patients to be monitored regularly to manage any adverse effects that may arise during treatment.
Research and Future Directions[edit]
Research is ongoing to further understand the long-term effects of aficamten and its potential use in other cardiac conditions. Studies are also exploring the combination of aficamten with other therapies to enhance its therapeutic effects.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
